1. 3056 Influence of maintenance therapy on incidence of 2nd line therapy and OS in NSCLC IV. (September 2015) Authors: Lüers, A.; Neemann, N.; Prenzel, R.; Scriba, D.; Hoheisel, M.; Wedeken, K.; Willborn, K.; Griesinger, F. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S614 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 3119 P53 disruptive mutation is a negative predictive factor in EGFR M+ NSCLC treated with TKI. (September 2015) Authors: Lüers, A.; Neemann, N.; Prenzel, R.; Scriba, D.; Willborn, K.; Stropiep, U.; Falk, M.; Hallas, C.; Tiemann, M.; Griesinger, F. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S643 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗